前列舒通胶囊联合特拉唑嗪对Ⅲ型慢性前列腺炎患者前列腺液中细胞因子的影响

Effects of Qianlie Shutong capsules combined with Terazosin on cytokines in prostate fluid of patients with chronic prostatitis

目的:探讨前列舒通胶囊联合特拉唑嗪治疗Ⅲ型慢性前列腺炎患者的效果及对前列腺液(EPS)中细胞因子的影响。方法:回顾性分析2019年1—12月于该院接受治疗的85例Ⅲ型慢性前列腺炎患者的临床资料,按治疗方案不同分为对照组(特拉唑嗪,42例)与观察组(前列舒通胶囊联合特拉唑嗪,43例)。两组均连续治疗8周,比较两组疗效,治疗前后EPS细胞因子水平,并比较两组治疗期间不良反应发生率。结果:观察组治疗总有效率(90.70%)高于对照组(73.81%),差异有统计学意义(P<0.05);治疗后,两组EPS中前列腺素E2、肿瘤坏死因子-α及增殖细胞核抗原水平均低于治疗前,且观察组较对照组更低,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:前列舒通胶囊与特拉唑嗪联合治疗Ⅲ型慢性前列腺炎患者效果显著,能改善患者EPS细胞因子水平,且不会增加不良反应。

Objective:To explore effects of Qianlie Shutong capsules combined with Terazosin in treatment of type III chronic prostatitis and its influence on cytokines in prostatic fluid(EPS).Methods:The clinical data of 85 patients with type III chronic prostatitis treated in our hospital in January to December 2019 were analyzed retrospectively.According to different drug treatment programs,they were divided into control group(Terazosin,42 cases)and observation group(Qianlie Shutong capsules combined with Terazosin,43 cases).Both groups were treated continuously for 8 weeks.The clinical effects and the levels of EPS cytokines before and after the treatment of the two groups were compared.Further,the occurrence of adverse reactions during the treatment of the two groups was statistically analyzed.Results:The total clinical effective rate(90.70%)of the observation group was higher than that of the control group(73.81%),and the difference was statistically significant(P<0.05).After the treatment,the levels of prostaglandin E2,tumor necrosis factor-αand proliferating cell nuclear antigen in EPS of the two groups were lower than those before the treatment;those of the observation group were lower than those of the control group;and the differences were statistically significant(P<0.05).However,there was no statistical difference in the incidence of adverse reactions between the observation group(18.60%)and the control group(14.29%)(P>0.05).Conclusions:Qianlie Shutong capsules combined with Terazosin in the treatment of the patients with type III chronic prostatitis has a significant effect,which can improve the patients’EPS cytokine levels without increasing adverse reactions.